期刊文献+

西部地区部分省份药品不良反应报告主体实证研究 被引量:2

Investigation on Work State of Adverse Drug Reaction Reporting in Some West Provinces
下载PDF
导出
摘要 目的调查西部地区部分省份药品不良反应(ADR)报告主体的工作现状,分析其存在的问题以提出切实可行的建议。方法以陕西和四川省药品生产企业、药品经营企业、医疗机构为研究对象,采用问卷调查法,进行抽样调查,使用SPSS 18.0统计软件对回收问卷所得数据处理分析。结果回收有效问卷198份,可基本了解西部地区部分省份各ADR报告主体关于ADR工作的现状,包括机构设置、人员配备、制度建设、经费支持、培训学习、报告情况、工作评价等基本情况。结论西部地区部分省份关于不良反应监测部门建设情况良好;在人员的培训学习方面,陕西省有待进一步加强。关于ADR工作的人员、经费、信息反馈等方面提出相关建议。 Objective To investigate the present situation of ADR monitoring of the reporting entities in some west provinces and analyze the existing problems and provide practical recommendations. Methods The drug manufacturers, drug distributors and medical institutions of Shanxi and Sichuan province were employed as the subjects. The returned questionnaires were analyzed via SPSS 18.0. Results 198 questionnaires were received. The informations of the ADR monitoring present situation were obtained in terms of structure, staff, system, fund, training, reporting and valuation. Conclusion The ADR monitoring situation was in good condition. It is necessary to strengthen the training in Shanxi province, and the staff, fund, information feedback should be improved.
出处 《中国药物警戒》 2015年第12期740-743,共4页 Chinese Journal of Pharmacovigilance
基金 国家社会科学基金资助项目(13BGL132)
关键词 陕西和四川省 药品不良反应 药品生产企业 药品经营企业 医疗机构 Shanxi and Sichuan province ADR drug manufacturer drug distributor medical institution
  • 相关文献

参考文献4

  • 1中华人民共和国全国人民代表大会常务委员会.中华人民共和国药品管理法(主席令第45号)[EB/OL].(2001-02-28)[2015-07-01].http://www.sda.gov.cn/WS01/CL0784/23396.html.
  • 2Olsson M S, Pal S N, Stergachis A, et al. Pharmacovigilance Activities in 55 Low-and Middle-Income Countries[J]. Drug safety, 2010, 33(8): 689-703.
  • 3刘花,冯变玲,杨世民,张智.我国省级药品不良反应监测机构发展现状的调查分析[J].中国药房,2014,25(12):1062-1066. 被引量:9
  • 4中华人民共和国卫生部.药品不良反应报告和监测管理办法(卫生部令第81号)[EB,OL].(2011-05-04)[2015-07-01].http://www.sda.gov.cn/WS0l/cL0053/62621.html.

二级参考文献9

  • 1国务院.关于深化医药卫生体制改革的意见[EB,OL].[2009-3-17].http://www.gov.crggongbao/content/2009/content_1284372.htm.
  • 2国务院国家药品安全"十二五"规划[EB,0L].[2012-2-13].http://www.gov.cn/zwgk/2012-02/13/cOntem_2065197.him.
  • 3USAID. Indicator-Based Pharmacovigilance Assessment Tool: Manual for Conducting Assessments in Developing Countries[R]. USAID, 2009.
  • 4WHO.Minimum Requirements for a functional Pharmaco- vigilance System[EB/OL ].[2012-5-21]. http ://www.who. int/.../entity/medicines/areas/quality_safety/safety_effica- cy/PV_Minimum Requirements 2010_2.pdf.
  • 5Brian E, Hugh HT, Suzanne L. Defining the competen- cies of those conducting Pharmacovigilance[J]. Pharmaco- epidemiology and Drug Safety, 2006(15) : 193.
  • 6Nwokike J, Eghan K. Pharmaeovigilance in Ghana:A Sy- stems Analysis[R ].USAID , 2010.
  • 7Nwokike J, Joshi M. Assessment of Pharmacovigilance and Medicine Safety System in Rwanda[R].USAID, 2009.
  • 8WHO. Medicines:safety of medicines-adverse drug reae- tions[EB/OL]. [2008-10]. http ://www.who.int/mediacentr- e/factsheets/fs293/en/index.html.
  • 9谢金洲,周勇,田月洁,黄传海,陈易新.我国省级药品不良反应监测机构模式研究[J].中国药物警戒,2009,6(1):8-12. 被引量:7

共引文献8

同被引文献20

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部